Nasdaq:US$18.72 (-0.96) | HKEX:HK$29.80 (-0.55) | AIM:£3.04 (-0.09)
News & Presentations
Previous Article   |   Next Article
Presentations | 18 Apr 2023

AACR 2023: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies